BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cabozantinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cabozantinib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05168618-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05168618)
DESCRIPTION:Cabozantinib\, phase 2\, Prostate Cancer.\nStudy: Cabozantinib 
 and Atezolizumab for the Treatment of Metastatic Castration-Resistant Pros
 tate Cancer\nEstimated primary completion: November 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05168618
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05613894-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cabozantinib: Phase 1 readout est. (NCT05613894)
DESCRIPTION:Cabozantinib\, phase 1\, Prostate Cancer.\nStudy: Dose-Escalati
 on Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617
  in Patients With Metastatic Castration-Resistant Prostate Cancer\nEstimat
 ed primary completion: December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05613894
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05182164-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05182164)
DESCRIPTION:Cabozantinib\, phase 2.\nStudy: Combination of Pembrolizumab an
 d Cabozantinib in Patients With Advanced Sarcomas\nEstimated primary compl
 etion: December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /cabozantinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05182164
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05425004-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05425004)
DESCRIPTION:Cabozantinib\, phase 2.\nStudy: Cabozantinib for Patients With 
 Recurrent or Progressive Meningioma\nEstimated primary completion: Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/cabozantinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0542
 5004
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05263050-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05263050)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Trial of
  an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carc
 inoma and Neuroendocrine Tumors\nEstimated primary completion: December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/cabozantinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05263050
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04413123-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT04413123)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Cabozant
 inib In Combo With NIVO + IPI In Advanced NCCRCC\nEstimated primary comple
 tion: 20 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/cabozantinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04413123
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06026410-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Cabozantinib: Phase 1 readout est. (NCT06026410)
DESCRIPTION:Cabozantinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: KO
 -2806 Monotherapy and Combination Therapies in Advanced Solid Tumors\nEsti
 mated primary completion: January 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06026410
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05136196-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05136196)
DESCRIPTION:Cabozantinib\, phase 2.\nStudy: BiCaZO: A Study Combining Two I
 mmunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advance
 d Melanoma or Squamous Cell Head and Neck Cancer\, an immunoMATCH Pilot St
 udy\nEstimated primary completion: 1 January 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05136196
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05122546-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:Cabozantinib: Phase 1 readout est. (NCT05122546)
DESCRIPTION:Cabozantinib\, phase 1\, Clear Cell Renal Cell Carcinoma.\nStud
 y: CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment
  of Advanced or Metastatic Kidney Cancer\nEstimated primary completion: 12
  January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/caboza
 ntinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05122546
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04472767-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT04472767)
DESCRIPTION:Cabozantinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Cabo
 zantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepa
 tocellular Carcinoma\nEstimated primary completion: 31 January 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04472767
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06835972-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Cabozantinib: Phase 1/2 readout est. (NCT06835972)
DESCRIPTION:Cabozantinib\, phase 1/2\, Clear Cell Renal Cell Carcinoma.\nSt
 udy: A Study of Abemaciclib and Cabozantinib in People With Clear Cell Ren
 al Cell Carcinoma (ccRCC)\nEstimated primary completion: February 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06835972
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04551430-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT04551430)
DESCRIPTION:Cabozantinib\, phase 2.\nStudy: Cabozantinib Combined With PD-1
  and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma\nEstimated primar
 y completion: 1 February 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/cabozantinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04551430
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03634540-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT03634540)
DESCRIPTION:Cabozantinib\, phase 2\, Clear Cell Renal Cell Carcinoma.\nStud
 y: A Trial of Belzutifan (PT2977\, MK-6482) in Combination With Cabozantin
 ib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)\
 nEstimated primary completion: 26 February 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT03634540
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03866382-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT03866382)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Testing 
 the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) Wi
 th One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tum
 ors\nEstimated primary completion: 28 February 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03866382
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05241561-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05241561)
DESCRIPTION:Cabozantinib\, phase 2.\nStudy: Cabo-POLARIS : A Trial to Evalu
 ate Cabozantinib Among Haemodialysied Patients\nEstimated primary completi
 on: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/caboz
 antinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05241561
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04310007-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT04310007)
DESCRIPTION:Cabozantinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Te
 sting the Addition of the Pill Chemotherapy\, Cabozantinib\, to the Standa
 rd Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-smal
 l Cell Lung Cancer\nEstimated primary completion: 31 March 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04310007
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187869-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270407
DTEND;VALUE=DATE:20270408
SUMMARY:Cabozantinib: Phase 1 readout est. (NCT07187869)
DESCRIPTION:Cabozantinib\, phase 1\, Clear Cell Renal Cell Carcinoma.\nStud
 y: Modulation of the Bone Immune Microenvironment Following Cabozantinib T
 reatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Conc
 ept Study\nEstimated primary completion: 7 April 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07187869
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04322955-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT04322955)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: CYTO Red
 uctive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inh
 ibition\nEstimated primary completion: May 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04322955
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01639508-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT01639508)
DESCRIPTION:Cabozantinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ca
 bozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lu
 ng Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increase
 d MET or AXL Activity\nEstimated primary completion: July 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT01639508
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05111574-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05111574)
DESCRIPTION:Cabozantinib\, phase 2.\nStudy: Using Nivolumab Alone or With C
 abozantinib to Prevent Mucosal Melanoma Return After Surgery\nEstimated pr
 imary completion: 15 July 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/cabozantinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05111574
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02496208-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Cabozantinib: Phase 1 readout est. (NCT02496208)
DESCRIPTION:Cabozantinib\, phase 1\, Clear Cell Renal Cell Carcinoma.\nStud
 y: Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treat
 ing Patients With Metastatic Genitourinary Tumors\nEstimated primary compl
 etion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 cabozantinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT02496208
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03541902-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT03541902)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Cabozant
 inib or Sunitinib Malate in Treating Participants With Metastatic Variant 
 Histology Renal Cell Carcinoma\nEstimated primary completion: 31 July 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cabozantinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT03541902
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03635892-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT03635892)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: A Study 
 of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear C
 ell Renal Cell Carcinoma\nEstimated primary completion: August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03635892
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05048901-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Cabozantinib: Phase 1/2 readout est. (NCT05048901)
DESCRIPTION:Cabozantinib\, phase 1/2.\nStudy: Cabozantinib and Lanreotide a
 s Treatment for Gastroenteropancreatic Neuroendocrine Tumors\nEstimated pr
 imary completion: 31 August 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/cabozantinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05048901
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Cabozantinib\, phase 2.\nStudy: The Drug Rediscovery Protocol (
 DRUP Trial)\nEstimated primary completion: September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07077161-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT07077161)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Cabozant
 inib Dose Skipping as an Alternative to Dose Reductions\nEstimated primary
  completion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/cabozantinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07077161
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05931393-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05931393)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Sequenti
 al Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)\nEsti
 mated primary completion: 1 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05931393
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05361720-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05361720)
DESCRIPTION:Cabozantinib\, phase 2\, Clear Cell Renal Cell Carcinoma.\nStud
 y: Genetic Testing to Select Therapy for the Treatment of Advanced or Meta
 static Kidney Cancer\, OPTIC RCC Study\nEstimated primary completion: 1 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cabozanti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05361720
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05663710-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Cabozantinib: Phase 1/2 readout est. (NCT05663710)
DESCRIPTION:Cabozantinib\, phase 1/2\, Clear Cell Renal Cell Carcinoma.\nSt
 udy: Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib 
 and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC\nE
 stimated primary completion: 30 October 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05663710
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06156410-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Cabozantinib: Phase 1 readout est. (NCT06156410)
DESCRIPTION:Cabozantinib\, phase 1.\nStudy: Cabozantinib With Ifosfamide in
  Relapsed/Refractory Sarcomas\nEstimated primary completion: November 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cabozantinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06156410
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06132945-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Cabozantinib: Phase 1 readout est. (NCT06132945)
DESCRIPTION:Cabozantinib\, phase 1\, Renal Cell Carcinoma.\nStudy: A Study 
 of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal
  Cell Carcinoma That Has Spread to the Brain\nEstimated primary completion
 : November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cabo
 zantinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06132945
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04878029-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271113
DTEND;VALUE=DATE:20271114
SUMMARY:Cabozantinib: Phase 1 readout est. (NCT04878029)
DESCRIPTION:Cabozantinib\, phase 1.\nStudy: Cabozantinib in Combination Wit
 h Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer\
 nEstimated primary completion: 13 November 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04878029
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05249114-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cabozantinib: Phase 1 readout est. (NCT05249114)
DESCRIPTION:Cabozantinib\, phase 1.\nStudy: Study of Cabozantinib With Lu-1
 77 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
 \nEstimated primary completion: December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05249114
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06006013-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271216
DTEND;VALUE=DATE:20271217
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT06006013)
DESCRIPTION:Cabozantinib\, phase 2.\nStudy: Cabozantinib in Combination Wit
 h Pembrolizumab for the Treatment of Patients With Locally Advanced\, Meta
 static\, or Unresectable Adrenal Cortical Cancer\nEstimated primary comple
 tion: 16 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/cabozantinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06006013
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05039281-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cabozantinib: Phase 1/2 readout est. (NCT05039281)
DESCRIPTION:Cabozantinib\, phase 1/2.\nStudy: Atezolizumab and Cabozantinib
  for the Treatment of Recurrent Glioblastoma\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 abozantinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05039281
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04588051-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT04588051)
DESCRIPTION:Cabozantinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Cabo
 zantinib in Hepatocellular Carcinoma\nEstimated primary completion: 31 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cabozanti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04588051
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05019703-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05019703)
DESCRIPTION:Cabozantinib\, phase 2.\nStudy: Atezolizumab and Cabozantinib f
 or the Treatment of Adolescents and Young Adults With Recurrent or Metasta
 tic Osteosarcoma\, TACOS Study\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/cabozantinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT050197
 03
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05048212-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05048212)
DESCRIPTION:Cabozantinib\, phase 2\, Renal Cell Carcinoma.\nStudy: A Phase 
 II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Un
 treated Renal Cell Carcinoma Brain Metastases\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 cabozantinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05048212
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010393-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cabozantinib: Phase 4 readout est. (NCT07010393)
DESCRIPTION:Cabozantinib\, phase 4.\nStudy: Genotype-Driven Neoadjuvant The
 rapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07010393
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03793166-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Cabozantinib: Phase 3 readout est. (NCT03793166)
DESCRIPTION:Cabozantinib\, phase 3\, Clear Cell Renal Cell Carcinoma.\nStud
 y: Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Ni
 volumab With Cabozantinib for Patients With Advanced Kidney Cancer\, The P
 DIGREE Study\nEstimated primary completion: 1 March 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03793166
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03816345-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Cabozantinib: Phase 1 readout est. (NCT03816345)
DESCRIPTION:Cabozantinib\, phase 1.\nStudy: Testing an Immunotherapy Anti-c
 ancer Drug\, Nivolumab\, for Advanced Cancers in Patients With Autoimmune 
 Disorders\, AIM-NIVO\nEstimated primary completion: 30 March 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03816345
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06934057-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Cabozantinib: Phase 4 readout est. (NCT06934057)
DESCRIPTION:Cabozantinib\, phase 4\, Renal Cell Carcinoma.\nStudy: Cabozant
 inib and Nivolumab Among Older Patients With Renal Cell Carcinoma\nEstimat
 ed primary completion: April 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/cabozantinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06934057
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05836571-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05836571)
DESCRIPTION:Cabozantinib\, phase 2.\nStudy: Testing Ipilimumab and Nivoluma
 b Combination With or Without Cabozantinib in People >= 18 Years Old With 
 Advanced Soft Tissue Sarcoma\nEstimated primary completion: 15 May 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05836571
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07151326-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT07151326)
DESCRIPTION:Cabozantinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Cabo
 zantinib for Progressive HCC Post-first-line Immuno-oncologic Combination 
 Therapy\nEstimated primary completion: June 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07151326
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03539822-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Cabozantinib: Phase 1/2 readout est. (NCT03539822)
DESCRIPTION:Cabozantinib\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Ca
 bozantinib Plus Durvalumab With or Without Tremelimumab in Patients With G
 astroesophageal Cancer and Other Gastrointestinal Malignancies\nEstimated 
 primary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/cabozantinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03539822
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03768063-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:Cabozantinib: Phase 3 readout est. (NCT03768063)
DESCRIPTION:Cabozantinib\, phase 3.\nStudy: A Study in Patients Previously 
 Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezoliz
 umab Study\nEstimated primary completion: 5 July 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03768063
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05613413-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05613413)
DESCRIPTION:Cabozantinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Pa
 tients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)\nEsti
 mated primary completion: September 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05613413
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07028125-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Cabozantinib: Phase 4 readout est. (NCT07028125)
DESCRIPTION:Cabozantinib\, phase 4\, Renal Cell Carcinoma.\nStudy: Digital 
 Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib
  Plus Nivolumab for Advanced Clear-cell Renal Carcinoma\nEstimated primary
  completion: October 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/cabozantinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07028125
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05536141-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Cabozantinib: Phase 1 readout est. (NCT05536141)
DESCRIPTION:Cabozantinib\, phase 1\, Clear Cell Renal Cell Carcinoma.\nStud
 y: A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal
  Cell Carcinoma and Other Solid Tumors\nEstimated primary completion: Marc
 h 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/cabozantinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0553
 6141
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06900595-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20290602
DTEND;VALUE=DATE:20290603
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT06900595)
DESCRIPTION:Cabozantinib\, phase 2.\nStudy: Testing the Addition of an Anti
 -Cancer Drug\, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810
 )\, in Adolescents and Adults With Advanced Adrenocortical Cancer\nEstimat
 ed primary completion: 2 June 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06900595
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05092958-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20290715
DTEND;VALUE=DATE:20290716
SUMMARY:Cabozantinib: Phase 3 readout est. (NCT05092958)
DESCRIPTION:Cabozantinib\, phase 3.\nStudy: Testing the Addition of the Ant
 i-cancer Drug\, Cabozantinib\, to the Usual Immunotherapy Treatment\, Avel
 umab\, in Patients With Metastatic Urothelial Cancer\, MAIN-CAV Study\nEst
 imated primary completion: 15 July 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05092958
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03899155-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20290825
DTEND;VALUE=DATE:20290826
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT03899155)
DESCRIPTION:Cabozantinib\, phase 2.\nStudy: Pan Tumor Rollover Study\nEstim
 ated primary completion: 25 August 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03899155
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07293351-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20291128
DTEND;VALUE=DATE:20291129
SUMMARY:Cabozantinib: Phase 1/2 readout est. (NCT07293351)
DESCRIPTION:Cabozantinib\, phase 1/2\, Renal Cell Carcinoma.\nStudy: A Stud
 y to Evaluate the Safety\, Tolerability\, and Efficacy of Pumitamig Alone 
 or in Combination With Other Agents in Participants With Advanced Renal Ce
 ll Carcinoma (RCC) (ROSETTA RCC-208)\nEstimated primary completion: 28 Nov
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cabozanti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07293351
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07805122-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20300519
DTEND;VALUE=DATE:20300520
SUMMARY:Cabozantinib: Phase na readout est. (NCT07805122)
DESCRIPTION:Cabozantinib\, phase na\, Renal Cell Carcinoma.\nStudy: Intensi
 fied Monitoring of PhArmacology of Cabozantinib as a Tool for Toxicity Man
 agement in Patients With Renal Cell Carcinoma\nEstimated primary completio
 n: 19 May 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/caboz
 antinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07805122
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620574-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Cabozantinib: Phase 3 readout est. (NCT07620574)
DESCRIPTION:Cabozantinib\, phase 3\, Hepatocellular Carcinoma.\nStudy: Long
 -Term Extension Study for Participants Previously Enrolled in an Exelixis-
 Sponsored Study\nEstimated primary completion: 31 May 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07620574
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06475989-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Cabozantinib: Phase 3 readout est. (NCT06475989)
DESCRIPTION:Cabozantinib\, phase 3.\nStudy: Study of Targeted Therapy vs. C
 hemotherapy in Patients With Thyroid Cancer\nEstimated primary completion:
  30 September 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 abozantinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06475989
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07194044-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Cabozantinib: Phase 1 readout est. (NCT07194044)
DESCRIPTION:Cabozantinib\, phase 1.\nStudy: Metastatic Ewing's Trial Testin
 g Schedule Enhancement to Improve Outcomes\nEstimated primary completion: 
 October 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cabozan
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07194044
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07848295-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20301018
DTEND;VALUE=DATE:20301019
SUMMARY:Cabozantinib: Phase 1 readout est. (NCT07848295)
DESCRIPTION:Cabozantinib\, phase 1\, Clear Cell Renal Cell Carcinoma.\nStud
 y: A Study to Assess the Safety and Tolerability of BMS-986527 in Particip
 ants With Clear Cell Renal Cell Carcinoma (ccRCC)\nEstimated primary compl
 etion: 18 October 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/cabozantinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07848295
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364631-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20320505
DTEND;VALUE=DATE:20320506
SUMMARY:Cabozantinib: Phase 3 readout est. (NCT06364631)
DESCRIPTION:Cabozantinib\, phase 3.\nStudy: CARE1 Pragmatic Clinical Trial\
 nEstimated primary completion: 5 May 2032. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06364631
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06502171-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20330801
DTEND;VALUE=DATE:20330802
SUMMARY:Cabozantinib: Phase 1 readout est. (NCT06502171)
DESCRIPTION:Cabozantinib\, phase 1.\nStudy: Study of Cabozantinib With Selu
 metinib for Plexiform Neurofibromas\nEstimated primary completion: 1 Augus
 t 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/cabozantinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0650
 2171
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405164-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20340422
DTEND;VALUE=DATE:20340423
SUMMARY:Cabozantinib: Phase 3 readout est. (NCT07405164)
DESCRIPTION:Cabozantinib\, phase 3.\nStudy: Extension Study for Participant
 s in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)\nEstimate
 d primary completion: 22 April 2034. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07405164
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871864-2031@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20350131
DTEND;VALUE=DATE:20350201
SUMMARY:Cabozantinib: Phase 3 readout est. (NCT07871864)
DESCRIPTION:Cabozantinib\, phase 3.\nStudy: Fight Osteosarcoma Through Euro
 pean Research Evolving Study Platform From Diagnosis to Relapse\nEstimated
  primary completion: January 2035. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/cabozantinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07871864
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
